TRUEBLUE INC (TBI) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:TBI - US89785X1019 - Common Stock
4.585 USD
-0.12 (-2.45%)
Overall TBI gets a fundamental rating of 3 out of 10. We evaluated TBI against 86 industry peers in the Professional Services industry. While TBI seems to be doing ok healthwise, there are quite some concerns on its profitability. TBI has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year TBI has reported negative net income.
In the past year TBI has reported a negative cash flow from operations.
In multiple years TBI reported negative net income over the last 5 years.
Of the past 5 years TBI 4 years had a positive operating cash flow.
1.2 Ratios
The Return On Assets of TBI (-4.07%) is worse than 67.44% of its industry peers.
The Return On Equity of TBI (-9.24%) is worse than 66.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.07% | ||
| ROE | -9.24% | ||
| ROIC | N/A |
ROA(3y)-4.7%
ROA(5y)-4.52%
ROE(3y)-10.14%
ROE(5y)-10.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TBI's Gross Margin of 24.02% is on the low side compared to the rest of the industry. TBI is outperformed by 68.60% of its industry peers.
TBI's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for TBI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 24.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.19%
GM growth 5Y-0.39%
2. Health
2.1 Basic Checks
TBI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TBI has been reduced compared to 1 year ago.
TBI has less shares outstanding than it did 5 years ago.
TBI has a worse debt/assets ratio than last year.
2.2 Solvency
TBI has an Altman-Z score of 3.30. This indicates that TBI is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of TBI (3.30) is better than 62.79% of its industry peers.
TBI has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
TBI has a Debt to Equity ratio (0.22) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.3 |
ROIC/WACCN/A
WACC9.15%
2.3 Liquidity
TBI has a Current Ratio of 2.01. This indicates that TBI is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 2.01, TBI is doing good in the industry, outperforming 74.42% of the companies in the same industry.
TBI has a Quick Ratio of 2.01. This indicates that TBI is financially healthy and has no problem in meeting its short term obligations.
TBI's Quick ratio of 2.01 is fine compared to the rest of the industry. TBI outperforms 76.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.01 | ||
| Quick Ratio | 2.01 |
3. Growth
3.1 Past
The earnings per share for TBI have decreased strongly by -31.43% in the last year.
The Revenue has decreased by -5.37% in the past year.
Measured over the past years, TBI shows a decrease in Revenue. The Revenue has been decreasing by -7.93% on average per year.
EPS 1Y (TTM)-31.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%127.27%
Revenue 1Y (TTM)-5.37%
Revenue growth 3Y-10.33%
Revenue growth 5Y-7.93%
Sales Q2Q%12.79%
3.2 Future
TBI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 58.41% yearly.
The Revenue is expected to grow by 3.38% on average over the next years.
EPS Next Y-14.47%
EPS Next 2Y60.97%
EPS Next 3Y58.41%
EPS Next 5YN/A
Revenue Next Year2.84%
Revenue Next 2Y3.94%
Revenue Next 3Y3.38%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TBI. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 17.24 indicates a rather expensive valuation of TBI.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TBI indicates a somewhat cheap valuation: TBI is cheaper than 60.47% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 24.01. TBI is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 17.24 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TBI's earnings are expected to grow with 58.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y60.97%
EPS Next 3Y58.41%
5. Dividend
5.1 Amount
TBI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSE:TBI (12/23/2025, 2:37:16 PM)
4.585
-0.12 (-2.45%)
Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryProfessional Services
Earnings (Last)
Earnings (Next)
Inst Owners97.67%
Inst Owner Change3.24%
Ins Owners5.15%
Ins Owner Change-0.24%
Market Cap137.27M
Revenue(TTM)1.58B
Net Income(TTM)-28.13M
Analysts80
Price Target8.67 (89.09%)
Short Float %4.64%
Short Ratio5.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)82.46%
Min EPS beat(2)28.92%
Max EPS beat(2)136%
EPS beat(4)3
Avg EPS beat(4)57%
Min EPS beat(4)-24.74%
Max EPS beat(4)136%
EPS beat(8)6
Avg EPS beat(8)53.54%
EPS beat(12)8
Avg EPS beat(12)35.65%
EPS beat(16)11
Avg EPS beat(16)35.09%
Revenue beat(2)1
Avg Revenue beat(2)1.18%
Min Revenue beat(2)-2.04%
Max Revenue beat(2)4.4%
Revenue beat(4)2
Avg Revenue beat(4)0.7%
Min Revenue beat(4)-2.04%
Max Revenue beat(4)4.4%
Revenue beat(8)3
Avg Revenue beat(8)-0.22%
Revenue beat(12)3
Avg Revenue beat(12)-1.16%
Revenue beat(16)5
Avg Revenue beat(16)-0.62%
PT rev (1m)-1.92%
PT rev (3m)-1.92%
EPS NQ rev (1m)-966.6%
EPS NQ rev (3m)-242.21%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.48%
Revenue NQ rev (1m)0.27%
Revenue NQ rev (3m)0.6%
Revenue NY rev (1m)1.56%
Revenue NY rev (3m)1.56%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 17.24 | ||
| P/S | 0.09 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.45 | ||
| P/tB | 0.56 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.46
EYN/A
EPS(NY)0.27
Fwd EY5.8%
FCF(TTM)-2.18
FCFYN/A
OCF(TTM)-1.59
OCFYN/A
SpS52.9
BVpS10.16
TBVpS8.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.07% | ||
| ROE | -9.24% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 24.02% | ||
| FCFM | N/A |
ROA(3y)-4.7%
ROA(5y)-4.52%
ROE(3y)-10.14%
ROE(5y)-10.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.19%
GM growth 5Y-0.39%
F-Score3
Asset Turnover2.29
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 62.33% | ||
| Cap/Sales | 1.13% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.01 | ||
| Quick Ratio | 2.01 | ||
| Altman-Z | 3.3 |
F-Score3
WACC9.15%
ROIC/WACCN/A
Cap/Depr(3y)102.48%
Cap/Depr(5y)103.83%
Cap/Sales(3y)1.51%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%127.27%
EPS Next Y-14.47%
EPS Next 2Y60.97%
EPS Next 3Y58.41%
EPS Next 5YN/A
Revenue 1Y (TTM)-5.37%
Revenue growth 3Y-10.33%
Revenue growth 5Y-7.93%
Sales Q2Q%12.79%
Revenue Next Year2.84%
Revenue Next 2Y3.94%
Revenue Next 3Y3.38%
Revenue Next 5YN/A
EBIT growth 1Y22.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year115.73%
EBIT Next 3Y37.45%
EBIT Next 5YN/A
FCF growth 1Y-325.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-179.24%
OCF growth 3YN/A
OCF growth 5YN/A
TRUEBLUE INC / TBI FAQ
Can you provide the ChartMill fundamental rating for TRUEBLUE INC?
ChartMill assigns a fundamental rating of 3 / 10 to TBI.
What is the valuation status for TBI stock?
ChartMill assigns a valuation rating of 2 / 10 to TRUEBLUE INC (TBI). This can be considered as Overvalued.
What is the profitability of TBI stock?
TRUEBLUE INC (TBI) has a profitability rating of 1 / 10.
How financially healthy is TRUEBLUE INC?
The financial health rating of TRUEBLUE INC (TBI) is 6 / 10.
Can you provide the expected EPS growth for TBI stock?
The Earnings per Share (EPS) of TRUEBLUE INC (TBI) is expected to decline by -14.47% in the next year.